Currently Enrolling

Currently Enrollingjsukhram2020-05-19T19:25:41+00:00

#	Category	Status	Study
1	C DIFF	Currently Enrolling	SMT19969/C004 A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of Ridinalazole for 10 days with Vancomycin for 10 days in the treatment of Clostridium difficile (C Diff) Infection Major Inclusion/Exclusion Criteria Have signs and symptoms associated with CDI including >3 unformed bowel movements in the last 24 hours Have not had more than one prior episode of CDI in the previous 3 months or more than 3 episodes in the past 12 months Have had no more than 24 hours of treatment with antimicrobial treatment active against CDI Does not have a diagnosis of inflammatory bowel disease (current or historical) Read more
2	COVID-19	Currently Enrolling	GS-US-540-5821 Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) Major Inclusion/Exclusion Criteria: Hospitalized with confirmed positive COVID-19 test 18 years or older On ventilator or tracheostomy Read more
3	HIV	Currently Enrolling	TMB-365-101 Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants Major Inclusion/Exclusion Criteria: Have not been on HIV medication for past 3 months HIV RNA between 1,000 and 100,000 copies CD4 >350 Read more
4	HIV	Currently Enrolling	TMC114FD2HTX4004 D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain Major Inclusion/Exclusion Criteria: Currently on Biktarvy, Genvoya, Tivicay/Descovy, or Isentress/Descovy for at least 6 months BMI >18 >10% increase in body weight within a 12 month period since starting medication HIV RNA <50 Read more
5	HIV	Currently Enrolling	M19-939 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1 Major Inclusion/Exclusion Criteria: On current HIV medication for at least 12 weeks HIV RNA <50 copies for 6 months CD4 >500 Willing to undergo ART interruption Read more
6	HIV	Currently Enrolling	GS-US-200-4625 A Phase 2/3 Study to Evaluate the Safety and Efficacy of GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Subjects with HIV-1 Infection. Major Inclusion/Exclusion Criteria: Multiple resistance to HIV therapy HIV RNA >500 copies Read more
7	HIV	Currently Enrolling	GS-US-200-4334 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV Major Inclusion/Exclusion Criteria: Never been on HIV medication HIV RNA >500 copies CD4 >200 No active Hepatitis B or Hepatitis C Read more
8	HIV	Currently Enrolling	MK8591A-020 Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection Major Inclusion/Exclusion Criteria: Never been on HIV medication HIV RNA between 500-100,00 copies Read more
9	HIV	Currently Enrolling	GS-US-380-5310 Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters Major Inclusion/Exclusion Criteria: HIV RNA <50 for 6 months Pregnancy between 12 weeks and 31 weeks at the time of Screening GFR >90 No Hepatitis B Infection Read more
10	HIV	Currently Enrolling	GS-US-380-4458 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adults Major Inclusion/Exclusion Criteria New diagnosis of HIV and Hepatitis B and never taken medications to treat Can not be co-infected with Hepatitis C Can not have decompensated cirrhosis Read more
11	HSV	Currently Enrolling	AIC316-03-II-01 A randomized, open label, multi-center, comparative trial, to assess the efficacy and safety of Pritelivir versus Foscarnet for the treatment of Acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults Major Inclusion/Exclusion Criteria Must be immunocompromised HSV lesion with clinical failure 5 days after using acyclovir, valacyclovir, or famciclovir HSV lesion accessible for size measurement and photography Read more